Adoptive immune cell therapy for colorectal cancer DOI Creative Commons
Chenxiao Liu, Nan Liu, Tongcun Zhang

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 1, 2025

Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality worldwide, with limited options for patients at advanced stages. Immunotherapy, particularly immune cell-based therapies, has gained significant attention as an innovative approach targeting CRC. This review summarizes the progress in various cell including DC vaccine, CAR/TCR-T cells, CAR-NK cells et al, each engineered to recognize attack expressing specific antigens. CAR-T therapy, which been successful hematologic cancers, faces challenges CRC due solid tumor microenvironment, limits infiltration persistence. CAR-M CAR-γδ T however, offer alternative strategies their unique properties, such ability target without prior sensitization lower risk inducing severe cytokine release syndrome. Recent advances lentiviral transduction have enabled effective expression CARs on NK γδ providing promising preclinical results models. explores mechanisms, targets, studies, early-phase clinical trials these addressing key enhancing specificity antigens overcoming immunosuppressive microenvironment. The potential combination checkpoint inhibitors also discussed some means improve effectiveness treatments Continued research essential translate approaches into settings, offering new hope patients.

Language: Английский

Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination DOI
Zhaokai Zhou, Yumiao Mai, Ge Zhang

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 598, P. 217079 - 217079

Published: June 25, 2024

Language: Английский

Citations

17
The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy DOI

Alberto Boretti

Computers in Biology and Medicine, Journal Year: 2024, Volume and Issue: 182, P. 109137 - 109137

Published: Sept. 10, 2024

Language: Английский

Citations

5
The multifaceted role of phosphodiesterase 4 in tumor: from tumorigenesis to immunotherapy DOI Creative Commons

Huimin Ren,

Shaohui Zhang, Peiyuan Li

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 10, 2025

Phosphodiesterase 4 (PDE4) is an enzyme that specifically hydrolyzes the second messenger cAMP and has a critical role in regulation of variety cellular functions. In recent years, PDE4 attracted great interest cancer research, its tumorigenesis development been gradually elucidated. Research indicates abnormal expression or heightened activity associated with initiation progression multiple cancers, including lung, colorectal, hematological by facilitating cell proliferation, migration, invasion, anti-apoptosis. Moreover, also influences tumor immune microenvironment, significantly evasion suppressing anti-tumor responses, reducing T-cell activation, promoting polarization tumor-associated macrophages toward pro-tumorigenic phenotype. However, family may have both oncogenic tumor-suppressive effects, which could depend on specific type grade tumor. inhibitors garnered substantial as potential anti-cancer therapeutics, directly inhibiting growth restoring surveillance capabilities to enhance clearance cells. Several are currently under investigation aim exploring their therapy, particularly combination strategies checkpoint inhibitors, improve therapeutic efficacy mitigate side effects conventional chemotherapy. This review provides overview tumorigenesis, drug resistance, immunotherapy, actions intending guide exploration new target therapy.

Language: Английский

Citations

0
Adoptive immune cell therapy for colorectal cancer DOI Creative Commons
Chenxiao Liu, Nan Liu, Tongcun Zhang

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 1, 2025

Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality worldwide, with limited options for patients at advanced stages. Immunotherapy, particularly immune cell-based therapies, has gained significant attention as an innovative approach targeting CRC. This review summarizes the progress in various cell including DC vaccine, CAR/TCR-T cells, CAR-NK cells et al, each engineered to recognize attack expressing specific antigens. CAR-T therapy, which been successful hematologic cancers, faces challenges CRC due solid tumor microenvironment, limits infiltration persistence. CAR-M CAR-γδ T however, offer alternative strategies their unique properties, such ability target without prior sensitization lower risk inducing severe cytokine release syndrome. Recent advances lentiviral transduction have enabled effective expression CARs on NK γδ providing promising preclinical results models. explores mechanisms, targets, studies, early-phase clinical trials these addressing key enhancing specificity antigens overcoming immunosuppressive microenvironment. The potential combination checkpoint inhibitors also discussed some means improve effectiveness treatments Continued research essential translate approaches into settings, offering new hope patients.

Language: Английский

Citations

0